A workflow to investigate exposure and pharmacokinetic influences on high-throughput in vitro chemical screening based on adverse outcome pathways

Environmental Health Perspectives

Volumn 124, Issue 1, 2016, Pages 53-60

  Phillips, Martin B ^a   Leonard, Jeremy A ^a   Grulke, Christopher M ^b   Chang, Daniel T ^c   Edwards, Stephen W ^d   Brooks, Raina ^e   Goldsmith, Michael Rock ^c   El Masri, Hisham ^d   Tan, Yu Mei ^f  

^a OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^b LOCKHEED MARTIN   (United States)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYLQUINOLINIUM CHLORIDE; ACETYLCHOLINESTERASE; BENDIOCARB; BESONPRODIL; BRONOPOL; CARBOFURAN; CARBOSULFAN; CHLORPYRIFOS; CRYSTAL VIOLET; DIDECYLDIMETHYLAMMONIUM CHLORIDE; DITHRANOL; DODECYLBENZENESULFONIC ACID; GW473178E; MERCURIC CHLORIDE; METHOMYL; MEVINPHOS; NALED; OXAMYL; PENTAMIDINE ISETHIONATE; PROPOXUR; QUINOLINE DERIVATIVE; RALOXIFENE; SB236057A; SR125047; SSR150106; SSR241586; SSR69071; TOLUENE DIISOCYANATE; UNCLASSIFIED DRUG; CHOLINESTERASE INHIBITOR;

ARTICLE; BLOOD BRAIN BARRIER; CHEMICAL ANALYSIS; CLEARANCE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENZYME INHIBITION; ENZYME INHIBITION ASSAY; HIGH THROUGHPUT SCREENING; METABOLIC ACTIVATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN TARGETING; RISK ASSESSMENT; TOXCAST ASSAY; TOXICITY ASSAY; WORKFLOW; HUMAN; IN VITRO STUDY; METABOLISM; PROCEDURES;

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IN VITRO TECHNIQUES; RISK ASSESSMENT; WORKFLOW;

EID: 84952683154     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1409450     Document Type: Article

References (81)

1. Abass K, Reponen P, Mattila S, Pelkonen O. 2010. Metabolism of carbosulfan II. Human inter-individual variability in its in vitro hepatic biotrans-formation and the identification of the cytochrome p450 isoforms involved. Chem Biol Interact 185:163–173.
2. Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, et al. 2010. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29:730–741.
3. Baell JB, Holloway GA. 2010. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719–2740.
4. Baell J, Walters MA. 2014. Chemistry: chemical con artists foil drug discovery. Nature 513:481–483.
5. Baldi P, Nasr R. 2010. When is chemical similarity significant? The statistical distribution of chemical similarity scores and its extreme values. J Chem Inf Model 50:1205–1222.
6. Beach JR, Campbell M, Andrews DJ. 1999. Exposure of health care workers to pentamidine isethionate. Occup Med (Lond) 49:243–245.
7. Beresford N, Routledge EJ, Harris CA, Sumpter JP. 2000. Issues arising when interpreting results from an in vitro assay for estrogenic activity. Toxicol Appl Pharmacol 162:22–33.
8. Berman T, Amitai Y, Almog S, Richter ED. 2012. Human biomonitoring in Israel: past, present, future. Int J Hyg Environ Health 215:138–141.
9. Berman T, Hochner-Celnikier D, Barr DB, Needham LL, Amitai Y, Wormser U, et al. 2011. Pesticide exposure among pregnant women in Jerusalem, Israel: results of a pilot study. Environ Int 37:198–203.
10. Bernhoft RA. 2012. Mercury toxicity and treatment: a review of the literature. J Environ Public Health 2012:460508; doi:10.1155/2012/460508.
11. Bertz RJ, Granneman GR. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210–258.
12. Boscolo M, Antonucci S, Volpe AR, Carmignani M, Di Gioacchino M. 2009. Acute mercury intoxication and use of chelating agents. J Biol Regul Homeost Agents 23:217–223.
13. Chambers JE, Carr RL. 1993. Inhibition patterns of brain acetylcholinesterase and hepatic and plasma aliesterases following exposures to three phosphorothionate insecticides and their oxons in rats. Fundam Appl Toxicol 21:111–119.
14. Chang DT, Goldsmith MR, Tornero-Velez R, Tan YM, Grulke CM, Chen LJ, et al. 2012. In silico strate-gies for modeling stereoselective metabolism of pyrethroids. In: Parameters for Pesticide QSAR and PBPK/PD Models for Human Risk Assessment (Knaak JB, Timchalk C, Tornero-Velez R, eds). New York:Oxford University Press, 245–269.
15. Clayton GD, Clayton FE, Patty FA, eds. 1994. Patty’s Industrial Hygiene and Toxicology. 4th ed. New York:John Wiley & Sons Inc.
16. Cochran RC, Formoli TA, Silva MH, Kellner TP, Lewis CM, Pfeifer KF. 1996. Risks from occupa-tional and dietary exposure to mevinphos. Rev Environ Contam Toxicol 146:1–24.
17. Cone M. 2010. Insecticide To Be Banned—Three Decades after Tainted Melons Sickened 2,000 People. Environmental Health News. Available: http://www.environmentalhealthnews.org/ehs/news/aldicarb-phaseout [accessed 27 October 2014].
18. Cui N, Zhang X, Xie Q, Wang S, Chen J, Huang L, et al. 2011. Toxicity profile of labile preservative bronopol in water: the role of more persistent and toxic transformation products. Environ Pollut 159:609–615.
19. Dejobert Y, Martin P, Piette F, Thomas P, Bergoend H. 1997. Contact dermatitis from didecyldimethyl-ammonium chloride and bis-(aminopropyl)-lauryl amine in a detergent-disinfectant used in hospital. Contact Dermatitis 37:95–96.
20. Dragos H, Gilles M, Alexandre V. 2009. Predicting the predictability: a unified approach to the applica-bility domain problem of QSAR models. J Chem Inf Model 49:1762–1776.
21. Duprey Z, Rivers S, Luber G, Becker A, Blackmore C, Barr D, et al. 2008. Community aerial mosquito control and naled exposure. J Am Mosq Control Assoc 24:42–46.
22. Eaton DL, Daroff RB, Autrup H, Bridges J, Buffler P, Costa LG, et al. 2008. Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment. Crit Rev Toxicol 38(suppl 2):1–125.
23. Egeghy PP, Judson R, Gangwal S, Mosher S, Smith D, Vail J, et al. 2012. The exposure data landscape for manufactured chemicals. Sci Total Environ 414:159–166.
24. EMEA (European Agency for the Evaluation of Medical Products). 1999. Committee for Medicinal Veterinary Products. Azamethiphos. Summary Report (1). EMEA/MRL//001/95-FINAL. London, UK:EMEA. Available: http://www.emea.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500010778.pdf [accessed 30 April 2015].
25. EXTOXNET (Extension Toxicology Network). 1993. Pesticide Information Profile: Oxamyl. Available: http://pmep.cce.cornell.edu/profiles/extoxnet/metiram-propoxur/oxamyl-ext.html [accessed 3 October 2014].
26. EXTOXNET (Extension Toxicology Network). 1996. Pesticide Information Profile: Methomyl. Available: http://extoxnet.orst.edu/pips/methomyl.htm [accessed 4 October 2014].
27. Goldsmith MR, Peterson SD, Chang DT, Transue TR, Tornero-Velez R, Tan YM, et al. 2012. Informing mechanistic toxicology with computational molecular models. Methods Mol Biol 929:139–165.
28. Groh KJ, Carvalho RN, Chipman JK, Denslow ND, Halder M, Murphy CA, et al. 2015. Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity: I. Challenges and research needs in ecotoxicology. Chemosphere 120:764–777.
29. Gupta RC. 1994. Carbofuran toxicity. J Toxicol Environ Health 43:383–418.
30. Hussain M, Yoshida K, Atiemo M, Johnston D. 1990. Occupational exposure of grain farmers to carbofuran. Arch Environ Contam Toxicol 19:197–204.
31. Houtappel M, Bruijnzeel-Koomen CA, Röckmann H. 2008. Immediate-type allergy by occupational exposure to didecyl dimethyl ammonium chloride. Contact Dermatitis 59:116–117.
32. Jaworska J, Nikolova-Jeliazkova N, Aldenberg T. 2005. QSAR applicabilty domain estimation by projec-tion of the training set descriptor space: a review. Altern Lab Anim 33:445–459.
33. Kapui Z, Varga M, Urban-Szabo K, Mikus E, Szabo T, Szeredi J, et al. 2003. Biochemical and pharmacological characterization of 2-(9-(2-piperidinoethoxy)-4-oxo-4H-pyrido[1,2-a] pyrimidin-2-yloxymethyl)-4-(1-methylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor. J Pharmacol Exp Ther 305:451–459.
34. Knudsen TB, Houck KA, Sipes NS, Singh AV, Judson RS, Martin MT, et al. 2011. Activity profiles of 309 ToxCast™ chemicals evaluated across 292 biochemical targets. Toxicology 282:1–15.
35. Kohlhaas KL, Rueter LE, Bitner RS. 2006. Alpha7 Neuronal Nicotinic Receptor Ligand and Anti-psychotic Compositions. U.S. Patent Application Publication. US2006/0211686 A1. Available: http://patentimages.storage.googleapis.com/pdfs/US20060211686.pdf [accessed 30 April 2015].
36. Kosaka K, Sakai N, Endo Y, Fukuhara Y, Tsuda-Tsukimoto M, Ohtsuka T, et al. 2011. Impact of intestinal glucuronidation on the pharmaco kinetics of raloxifene. Drug Metab Dispos 39:1495–1502.
37. Lapenna S, Gabbert S, Worth A. 2012. Training needs for toxicity testing in the 21st century: a surveyinformed analysis. Altern Lab Anim 40:313–320.
38. LeBlanc GA, Kullman SW, Norris DO, Baldwin WS, Kloas W, Greally JM. 2011. Draft Detailed Review Paper. State of the Science on Novel in Vitro and in Vivo Screening and Testing Methods and Endpoints for Evaluating Endocrine Disruptors. Research Triangle Park, NC:RTI International. Available: http://www.oecd.org/chemicalsafety/testing/49002244.pdf [accessed 30 April 2015].
39. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25.
40. Mackay D, Giesy JP, Solomon KR. 2014. Fate in the environment and long-range atmospheric transport of the organophosphorus insecticide, chlorpyrifos and its oxon. Rev Environ Contam Toxicol 231:35–76.
41. Mauri A, Consonni V, Pavan M, Todeschini R. 2006. DRAGON software: an easy approach to molecular descriptor calculations. Match-Commun Math Comput Chem 56:237–248.
42. McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. 2005. The anti-psoriatic drug anthralin accumulates in keratinocyte mito-chondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J 19:1012–1014.
43. Métro TX, Cochi A, Gomez Pardo D, Cossy J. 2011. Asymmetric synthesis of an antagonist of neurokinin receptors: SSR 241586. J Org Chem 76:2594–2602.
44. Montgomery AB, Corkery KJ, Brunette ER, Leoung GS, Waskin H, Debs RJ. 1990. Occupational exposure to aerosolized pentamidine. Chest 98:386–388.
45. NIOSH (National Institute for Occupational Safety and Health). 1983. NOES. National Occupational Exposure Survey Conducted from 1981 to 1983. Available: http://www.cdc.gov/noes/[accessed 24 October 2014].
46. Ostrea EM Jr., Villanueva-Uy E, Bielawski D, Birn S, Janisse JJ. 2014. Trends in long term exposure to propoxur and pyrethroids in young children in the Philippines. Environ Res 131:13–16.
47. Ouattara B, Belkhir S, Morissette M, Dridi M, Samadi P, Grégoire L, et al. 2009. Implication of NMDA recep-tors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. J Mol Neurosi 38:128–142.
48. R & D Focus Drug News. 2007. SSR 150106 Sanofi-Aventis Phase Change II, Europe(inflammation). Available: http://business.highbeam.com/436989/article-1G1-173125154/ssr-150106-sanofiaventis-phase-change-ii-europe [accessed 4 October 2014].
49. Rahman SA, Bashton M, Holliday GL, Schrader R, Thornton JM. 2009. Small molecule subgraph detector (SMSD) toolkit. J Cheminform 1:12; doi:10.1186/1758-2946-1-12.
50. Rautio J, Kumpulainen H, Heimbach T, Oliyai R, Oh D, Järvinen T, et al. 2008. Prodrugs: design and clinical applications. Nat Rev Drug Discov 7:255–270.
51. Roberts C, Watson J, Price GW, Middlemiss DN. 2001. SB-236057-A: a selective 5-HT1B receptor inverse agonist. CNS Drug Rev 7:433–444.
52. Roberts T, Hutson D. 1999. Macrocyclic insecticides. In: Metabolic Pathways of Agrochemicals: Part 2: Insecticides and Fungicides (Roberts TR, Hutson HD, Jewess PJ, Lee PW, Nicholls PH, Plimmer JR, eds). Cambridge, UK:Royal Society of Chemistry Publishing, 79–103.
53. Russom CL, LaLone CA, Villeneuve DL, Ankley GT. 2014. Development of an adverse outcome pathway for acetylcholinesterase inhibition leading to acute mortality. Environ Toxicol Chem 33:2157–2169.
54. Schilmann A, Lacasaña M, Blanco-Muñoz J, Aguilar-Garduño C, Salinas-Rodríguez A, Flores-Aldana M, et al. 2010. Identifying pesticide use patterns among flower growers to assess occupational exposure to mixtures. Occup Environ Med 67:323–329.
55. Sehgal VN, Verma P, Khurana A. 2014. Anthralin/dithranol in dermatology. Int J Dermatol 53:e449–e460.
56. Shlomi T, Cabili MN, Herrgård MJ, Palsson BØ, Ruppin E. 2008. Network-based prediction of human tissue-specific metabolism. Nat Biotechnol 26:1003–1010.
57. Smegal DC. 2000. Human Health Risk Assessment: Chlorpyrifos. Washington, DC:U.S. Environmental Protection Agency, Office of Pesticide Programs. Available: http://www.epa.gov/scipoly/sap/meetings/2008/september/hed_ra.pdf [accessed 30 April 2015].
58. Stanforth RW, Kolossov E, Mirkin B. 2007. A measure of domain of applicability for QSAR modelling based on intelligent K-means clustering. QSAR Comb Sci 26:837–844.
59. Steinbeck C, Han Y, Kuhn S, Horlacher O, Luttmann E, Willighagen E. 2003. The Chemistry Development Kit (CDK): an open-source Java library for chemo-and bioinformatics. J Chem Inf Comput Sci 43:493–500.
60. Tan YM, Sobus J, Chang D, Tornero-Velez R, Goldsmith M, Pleil J, et al. 2012. Reconstructing human exposures using biomarkers and other “clues.” J Toxicol Environ Health B Crit Rev 15:22–38.
61. TOXNET (Toxicology Data Network). 2002. Dodecyl Benzene Sulfonic Acid. CASRN: 27176-87-0. Available: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+6285 [accessed 30 April 2015].
62. TOXNET. 2013. Gentian Violet. CASRN: 548-62-9. Available: http://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+4366 [accessed 30 April 2015].
63. Travassos AR, Claes L, Boey L, Drieghe J, Goossens A. 2011. Non-fragrance allergens in specific cosmetic products. Contact Dermatitis 65:276–285.
64. UNM (University of New Mexico). 2014. Badapple. Available: http://pasilla.health.unm.edu/tomcat/badapple/badapple [accessed 9 October 2014].
65. U.S. EPA (U.S. Environmental Protection Agency). 1994. R.E.D. FACTS: Mevinphos. EPA-738-F-94-020; EPA-738-R-94-023. Washington, DC:U.S. EPA. Available: http://archive.epa.gov/pesticides/reregistration/web/pdf/0250fact.pdf [accessed 9 November 2015].
66. U.S. EPA. 2006. US Environmental Protection Agency. Office of Pesticide Programs. Reregistration Eligibility Decision for Naled. Available: http://archive.epa.gov/pesticides/reregistration/web.old/pdf/naled_red.pdf [accessed 9 November 2015].
67. U.S. EPA. 2008. Carbofuran I.R.E.D. Facts. Available: http://archive.epa.gov/pesticides/reregistration/web/html/carbofuran_ired_fs.html [accessed 9 November 2015].
68. U.S. EPA. 2010. Toxicity Forecaster (ToxCast™) Data. Available: http://www.epa.gov/ncct/toxcast/index.html [accessed 3 May 2015].
69. U.S. EPA. 2011. Chlorpyrifos: Preliminary Human Health Risk Assessment for Registration Review. EPA/HQ/OPP/2008/0850/0025. Washington, DC:U.S. EPA. Available: http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPP-2008-0850-0025 [accessed 9 November 2015].
70. U.S. EPA. 2012a. Risk Assessment. Human Health Risk Assessments. Available: http://www.epa.gov/risk_assessment/health-risk.htm [accessed 9 October 2014].
71. U.S. EPA. 2012b. Study of the Potential Impacts of Hydraulic Fracturing on Drinking Water Resources: Progress Report. EPA 601/R-12/011. Washington, DC:U.S. EPA. Available: http://www2.epa.gov/sites/production/files/documents/hf-report20121214.pdf [accessed 9 November 2015].
72. U.S. EPA. 2013. Technology Transfer Network–Air Toxics Web Site. Tolulene. Available: http://www3.epa.gov/airtoxics/hlthef/toluene.html [accessed 11 November 2015].
73. U.S. EPA. 2014a. Toxicity Forecasting: Advancing the Next Generation of Chemical Safety Evaluation. Available: http://www2.epa.gov/chemical-research/toxicity-forecasting [accessed 11 November 2014].
74. U.S. EPA. 2014b. TSCA Chemical Substance Inventory Homepage. Available: http://www.epa.gov/oppt/existingchemicals/pubs/tscainventory/[accessed 30 April 2015].
75. Van Scoy AR, Yue M, Deng X, Tjeerdema RS. 2013. Environmental fate and toxicology of methomyl. Rev Environ Contam Toxicol 222:93–109.
76. Vedani A, Smiesko M. 2009. In silico toxicology in drug discovery—concepts based on three-dimensional models. Altern Lab Anim 37:477–496.
77. Villeneuve DL, Crump D, Garcia-Reyero N, Hecker M, Hutchinson TH, LaLone CA, et al. 2014. Adverse outcome pathway development II: best practices. Toxicol Sci 142:321–330.
78. Vinken M, Landesmann B, Goumenou M, Vinken S, Shah I, Jaeschke H, et al. 2013. Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. Toxicol Sci 136:97–106.
79. Watanabe KH, Andersen ME, Basu N, Carvan MJ, Crofton KM, King KA, et al. 2011. Defining and modeling known adverse outcome pathways: domoic acid and neuronal signaling as a case study. Environ Toxicol Chem 30:9–21.
80. Willett P, Barnard JM, Downs GM. 1998. Chemical similarity searching. J Chem Inf Comp Sci 38:983–996.
81. Wyld PJ, Watson CE, Nimmo WS, Watson N. 1992. A Safety and Tolerability Study of Aldicarb at Various Dose Levels in Healthy Male and Female Volunteers. Rhone-Poulenc, Lyon, France. Inveresk Clinical Research Report No. 7786. MRID No. 423730-01. HED Doc. No. 0010459. Washington, DC:U.S. Environmental Protection Agency.